ARCHIVES

Ethicists dispute von Eschenbach’s claim that his NCI-FDA conflicts are managed. NCI-FDA chief appears to cite Klausner-era “in-box rule.”

This article is from The Cancer Letter archive.

Vol. 31 No. 46 | December 16, 2005

Download PDF Visit The Full Archive

Related Articles

Clinical Trial Pathology Improvements Recommended By Group Remaining Actions After Merit Review

January 12, 1979

Pathology Review Confirms Reserpine As Carcinogen

March 14, 1980

Zometa Better Than Placebo In Treatment Of Bone Mets

August 31, 2001

Senate Bill Would Prohibit Political Appointments To Advisory Groups

January 9, 1976

Surgical Oncology Status A Disaster, DCT board Told; Kramer Describes Radiotherapy Needs

April 20, 1979

Under Ultimatum, NIH Databases Remove “Misconduct” Tags From Papers By Fisher

February 24, 1995